Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 6/2009

01.06.2009 | Original Paper

Protein expression profiling of vascular endothelial growth factor and its receptors identifies subclasses of hepatocellular carcinoma and predicts survival

verfasst von: Jin-Bin Jia, Peng-Yuan Zhuang, Hui-Chuan Sun, Ju-Bo Zhang, Wei Zhang, Xiao-Dong Zhu, Yu-Quan Xiong, Hua-Xiang Xu, Zhao-You Tang

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 6/2009

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To examine expression profile and prognostic significance of vascular endothelial growth factor (VEGF) and its receptors in hepatocellular carcinoma (HCC) and peritumoral tissue.

Methods

Expression of VEGF-A, VEGF-C, and VEGF receptor 1(VEGFR-1), VEGFR-2, and VEGFR-3 in tumor and peritumoral liver tissue was studied by immunohistochemistry in a tissue microarray from 107 patients with HCC. Unsupervised hierarchical cluster analyses were conducted to identify relevant clusters.

Results

Staining of VEGF-A, VEGF-C, VEGFR-2, and VEGFR-3 was mostly found on the tumor cells and peritumoral hepatocytes, but VEGFR-1 was mostly expressed in stromal cells. In most of the cases, the expression of VEGF-A, VEGFR-1, VEGFR-2, and VEGFR-3 in was higher in peritumoral liver tissue, while VEGF-C expression was higher in tumor. Unsupervised hierarchical clustering analysis identified four prognostically different clusters, of which cluster A was classified into the “poor prognosis group,” and the other three clusters were classified into the “good prognosis group” (= 0.047). Further analysis with a set of seven markers reproduced the same four cluster groups with significantly different recurrence free probability (RFP) (= 0.018), and the low RFP group was associated with more intrahepatic satellite lesions. Multivariate analysis showed that classification defined by seven biomarkers was of prognostic significance (= 0.000).

Conclusions

Expression of VEGF and its receptors was higher in peritumoral tissue than in tumor in HCC. Seven biomarkers predicted patients’ RFP, which consisted of tumoral expression of VEGF-A, VEGFR-1, and VEGF-C as well as peritumoral expression of VEGF-A, VEGFR-1, VEGFR-2, and VEGFR-3.
Literatur
Zurück zum Zitat Au NH, Cheang M, Huntsman DG et al (2004) Evaluation of immunohistochemical markers in non-small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers. J Pathol 204:101–109. doi:10.1002/path.1612 PubMedCrossRef Au NH, Cheang M, Huntsman DG et al (2004) Evaluation of immunohistochemical markers in non-small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers. J Pathol 204:101–109. doi:10.​1002/​path.​1612 PubMedCrossRef
Zurück zum Zitat Budhu A, Forgues M, Ye QH et al (2006) Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 10:99–111. doi:10.1016/j.ccr.2006.06.016 PubMedCrossRef Budhu A, Forgues M, Ye QH et al (2006) Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 10:99–111. doi:10.​1016/​j.​ccr.​2006.​06.​016 PubMedCrossRef
Zurück zum Zitat El-Assal ON, Yamanoi A, Soda Y et al (1998) Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. Hepatology 27:1554–1562. doi:10.1002/hep.510270613 PubMedCrossRef El-Assal ON, Yamanoi A, Soda Y et al (1998) Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. Hepatology 27:1554–1562. doi:10.​1002/​hep.​510270613 PubMedCrossRef
Zurück zum Zitat Jacquemier J, Ginestier C, Rougemont J et al (2005) Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. Cancer Res 65:767–779PubMed Jacquemier J, Ginestier C, Rougemont J et al (2005) Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. Cancer Res 65:767–779PubMed
Zurück zum Zitat Kaposi-Novak P, Lee JS, Gomez-Quiroz L et al (2006) Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest 116:1582–1595. doi:10.1172/JCI27236 PubMedCrossRef Kaposi-Novak P, Lee JS, Gomez-Quiroz L et al (2006) Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest 116:1582–1595. doi:10.​1172/​JCI27236 PubMedCrossRef
Zurück zum Zitat Li XM, Tang ZY, Qin LX et al (1999) Serum vascular endothelial growth factor is a predictor of invasion and metastasis in hepatocellular carcinoma. J Exp Clin Cancer Res 18:511–517PubMed Li XM, Tang ZY, Qin LX et al (1999) Serum vascular endothelial growth factor is a predictor of invasion and metastasis in hepatocellular carcinoma. J Exp Clin Cancer Res 18:511–517PubMed
Zurück zum Zitat Makretsov NA, Huntsman DG, Nielsen TO et al (2004) Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma. Clin Cancer Res 10:6143–6151. doi:10.1158/1078-0432.CCR-04-0429 PubMedCrossRef Makretsov NA, Huntsman DG, Nielsen TO et al (2004) Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma. Clin Cancer Res 10:6143–6151. doi:10.​1158/​1078-0432.​CCR-04-0429 PubMedCrossRef
Zurück zum Zitat Price DJ, Miralem T, Jiang S et al (2001) Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells. Cell Growth Differ 12:129–135PubMed Price DJ, Miralem T, Jiang S et al (2001) Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells. Cell Growth Differ 12:129–135PubMed
Zurück zum Zitat Suzuki K, Hayashi N, Miyamoto Y et al (1996) Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma. Cancer Res 56:3004–3009PubMed Suzuki K, Hayashi N, Miyamoto Y et al (1996) Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma. Cancer Res 56:3004–3009PubMed
Zurück zum Zitat Toi M, Bando H, Ogawa T et al (2002) Significance of vascular endothelial growth factor (VEGF)/soluble VEGF receptor-1 relationship in breast cancer. Int J Cancer 98:14–18. doi:10.1002/ijc.10121 PubMedCrossRef Toi M, Bando H, Ogawa T et al (2002) Significance of vascular endothelial growth factor (VEGF)/soluble VEGF receptor-1 relationship in breast cancer. Int J Cancer 98:14–18. doi:10.​1002/​ijc.​10121 PubMedCrossRef
Zurück zum Zitat von Marschall Z, Cramer T, Hocker M et al (2001) Dual mechanism of vascular endothelial growth factor upregulation by hypoxia in human hepatocellular carcinoma. Gut 48:87–96. doi:10.1136/gut.48.1.87 CrossRef von Marschall Z, Cramer T, Hocker M et al (2001) Dual mechanism of vascular endothelial growth factor upregulation by hypoxia in human hepatocellular carcinoma. Gut 48:87–96. doi:10.​1136/​gut.​48.​1.​87 CrossRef
Zurück zum Zitat Yamaguchi R, Yano H, Nakashima Y et al (2000) Expression and localization of vascular endothelial growth factor receptors in human hepatocellular carcinoma and non-HCC tissues. Oncol Rep 7:725–729PubMed Yamaguchi R, Yano H, Nakashima Y et al (2000) Expression and localization of vascular endothelial growth factor receptors in human hepatocellular carcinoma and non-HCC tissues. Oncol Rep 7:725–729PubMed
Zurück zum Zitat Yu GR, Kim SH, Park SH et al (2007a) Identification of molecular markers for the oncogenic differentiation of hepatocellular carcinoma. Exp Mol Med 39:641–652PubMed Yu GR, Kim SH, Park SH et al (2007a) Identification of molecular markers for the oncogenic differentiation of hepatocellular carcinoma. Exp Mol Med 39:641–652PubMed
Zurück zum Zitat Zhu XD, Zhang JB, Zhuang PY et al (2008) High expression of macrophage colony-stimulating factor in peritumoral liver tissue associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol 26:2707–2716. doi:10.1200/JCO.2007.15.6521 PubMedCrossRef Zhu XD, Zhang JB, Zhuang PY et al (2008) High expression of macrophage colony-stimulating factor in peritumoral liver tissue associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol 26:2707–2716. doi:10.​1200/​JCO.​2007.​15.​6521 PubMedCrossRef
Metadaten
Titel
Protein expression profiling of vascular endothelial growth factor and its receptors identifies subclasses of hepatocellular carcinoma and predicts survival
verfasst von
Jin-Bin Jia
Peng-Yuan Zhuang
Hui-Chuan Sun
Ju-Bo Zhang
Wei Zhang
Xiao-Dong Zhu
Yu-Quan Xiong
Hua-Xiang Xu
Zhao-You Tang
Publikationsdatum
01.06.2009
Verlag
Springer-Verlag
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 6/2009
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-008-0521-0

Weitere Artikel der Ausgabe 6/2009

Journal of Cancer Research and Clinical Oncology 6/2009 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.